Gene therapy for cardiovascular diseases

Bibliography

• SCOTT-RAM NR: Gene therapy: review of recent patent activity. Exp. Opin. Ther. Patents (1995) 5(3):219–226.
   Google Scholar
• VERMA IM, SOMIA N: Gene therapy - promises, prob-lems, and prospects. Nature (1997) 389:239–242.
   PubMed Web of Science ®Google Scholar
• ••Good recent review of gene therapy.
   Google Scholar
• AMERICAN HEART ASSOCIATION (1997) Statistical Supple-ment: http://www.amhrt.org/1997/stats/Card Dise.html.
   Google Scholar
• ANDERSON KM, CASTELLI WP, LEVY D: Cholesterol andmortality: 30 years of followup from the Framingham Study. JAMA (1987) 257:2176–2180.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTAIN SURVIVAL STUDY GROUP:Randomized trial of cholesterol lowering in 4444 pa-tients with coronary artery disease. Scandinavian Sim-vastatin Survival Study (4S). Lancet (1 9 9 4) 344:1383–1389.
   Google Scholar
• CHANG G, RUGGERI RB: Recent developments in thetreatment of dyslipidemia. Exp. Opin. Ther. Patents (1997) 7(5):441–455.
   Web of Science ®Google Scholar
• SHEPHERD J, CABLE SM, FORD I et al: Prevention ofcoronary heart disease with pravastatin in men with. New Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBBINS SJ, COLLINS D et al: Distribution of lipids in 8500 men with coronary heart disease. Am. Cardiol (1995) 75:1196–1201.
   PubMed Web of Science ®Google Scholar
• STRAUSS WE, FORTIN T, HARTIGAN P et al: A compari-son of quality of life scores in patients with angina pec-toris after angioplasty compared with after medical therapy: outcomes of a randomized clinical trial. Cir-culation (1995) 42:1710–1719.
   Google Scholar
• TOPOL E, ELLIS S, COSGROVE D et al.: Analysis of coro-nary angioplasty practice in the US with an insurance - claims database. Circulation (1993) 87:1489–1497.
   PubMed Web of Science ®Google Scholar
• ECCLESTON ES, LINCOFF AM: Catheter-based drug deliv-ery for restenosis. Adv. Drug Deliver)/ Rev. (1997) 24:31–43.
   Google Scholar
• ROUBIN GS, DOUGLAS JS KING SB III et al: Influence of balloon size on institute success, acute complications and restenosis after percutaneous transluminal coro-nary angioplasty: a prospective randomized study. Circulation (1988) 78:557–565.
   PubMed Web of Science ®Google Scholar
• RUYGROK RN, SERRUYS PW: Intracoronary stenting: from concept to custom. Circulation (1996) 94:8820890.
   Google Scholar
• VERSACI F, GASPARDON A, TOMAI F et al.: A comparison of coronary artery stenting with angioplasty for iso-lated stenosis of the proximal left anterior descending coronary artery. New Engl. J. Med. (1997) 336:817–822.
   PubMed Web of Science ®Google Scholar
• FISHCMAN D, LEON M, BAIM D et al.: A randomized com-parison of coronary-stent placement and balloon an-gioplasty in treatment of coronary artery disease. New Engl. J. Med. (1994) 331:496–501.
   Google Scholar
• WARD M: The pathobiology of restenosis after percuta-neous revascularization: current concepts and thera-peutic objectives. Asia Pac. Heart J. (1997) 6:161–172.
   Google Scholar
• AEBERSOLD P, CORNETTA K et al: Gene transfer into - immunotherapy of patients with advanced melanoma using tumour-infiltrating lymphocyte modified by retroviral gene transduction. New Engl. J. Med. (1990) 323:570–578.
   Google Scholar
• ••First gene therapy protocol in the clinic.
   Google Scholar
• BLAESE RM, CULVER KW: Gene therapy for primary im-munodeficiency diseases. Immunodefic. Rev. (1992) 3:329–349.
   PubMedGoogle Scholar
• GROSSMAN M, RADER D, MULLER DWM et al: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med. (1995) 1:1148–1154.
   PubMed Web of Science ®Google Scholar
• ••First cardiovascular gene therapy protocol in the clinic.
   Google Scholar
• ISNER JM, PIECZEK A, SCHAINFELD R et al: Clinical evi-dence of angiogenesis after arterial gene transfer of phVEGF165 in patients with ischaemic limbs. Lancet (1996) 348:370–374.
   PubMed Web of Science ®Google Scholar
• CLOWES AW: Vascular gene therapy in the 21st cen-tury. Thrombosis Haemostasis (1997) 78(1)605–610.
   Google Scholar
• LEDLEY FD: Nonviral gene therapy: the promise of as pharmaceutical products. Human Gene Ther. (1995) 6:1129–1144.
   PubMed Web of Science ®Google Scholar
• •Review of non-viral gene therapy.
   Google Scholar
• ANDERSON WF: Human gene therapy. Science (1992)256:808–813.
   PubMed Web of Science ®Google Scholar
• FELGNER PL, GADEK TR, HELM M et al.: Lipofection: ahighly efficient lipid-mediated DNA-transfection pro-cedure. Proc. Nati Acad. Sci. USA (1987) 84:7413–7417.
   PubMed Web of Science ®Google Scholar
• CRYSTAL RG: The gene as the drug. Nature Med. (1995)1:15–17.
   PubMed Web of Science ®Google Scholar
• MARCH KL: Methods of local gene delivery to vascular tissue. Semin. Intervenf Cardiol (1996) 1:215–223.
   Google Scholar
• CRYSTAL RG: Transfer of genes to humans: early les-sons and obstacles to success. Science (1995) 270:404–410.
   PubMed Web of Science ®Google Scholar
• HAVENA M, FISHER R, HOOGERBRUGGE P et al.: Devel-opment of safe and efficient retroviral vectors for Gaucher's disease. Gene Ther. (1997) 4:1393–1400.
   Google Scholar
• SIKORA K: Gene therapy in the developing world. Gene Ther. (1998) 5:3–4.
   Google Scholar
• BROWN MS, GOLDSTEIN JL: A receptor-mediated path-way for cholesterol homeostasis. Science (1986) 232:34–47.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, KNOKE J, PROBSFIELD JL et al.: High den-sity lipoprotein cholesterol and coronary heart dis-ease in hypercholesterolemic men: The Lipid Research Clinic Coronary Primary Prevention Trial. Circulation (1986) 74:1217–1225.
   PubMed Web of Science ®Google Scholar
• MILLER NE: Association of high density lipoprotein subclass and apolipoprotein with ischaemic heart dis-ease and coronary atherosclerosis. Am. Heart J. (1987) 113:589–597.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JL, BROWN MS: Familial hypercholestero-laemia: lipoprotein and lipid metabolic disorders. In: Metabolic Basis of Inherited Disease (Edition 2). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), New York, McGraw-Hill (1989).
   Google Scholar
• WILSON JM, CHOWDHURY R, GROSSMAN M et al: Tem-porary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. Proc. Natl. Acad. Sci. USA (1990) 87:8437–8441.
   PubMed Web of Science ®Google Scholar
• BABIRAK SP, BROWN BG, BRUNZELL JD: Familial com-bined hyperlipidemia and abnormal lipoprotein li-pase. Arterioscler. Thromb. (1992) 12:1176–1183.
   Google Scholar
• KOZARSKY KF, DONAHU M, JOOSS K et al.: Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nature Genetic (1996) 13:54–62.
   PubMed Web of Science ®Google Scholar
• BIELICKI JK, MACALL1 MR, STOLZFUS LJ et al.: Evidence that apolipoprotein A-Imaano has reduced capacity, compared with wild-type apolipoprotein A-I to recruit membrane cholesterol. Arterioscler. Thromb. Vasc. (1997) 17:1637–1643.
   Google Scholar
• KARATHANASIS SK, NORUM RA, ZANNIS VI et al.: An in-herited polymorphism in the human apolipoprotein A-I gene locus related to development of atherosclero-sis. Nature (1983) 301:718–720.
   Google Scholar
• ORDOVAS JM, SCHAEFER EJ, SALIN D et al.: Apolipopro-tein A-I gene polymorphism associated with prema-ture coronary artery disease and familial hypoalphacholesterolemia. New Engl. J. Med. (1986) 314:671–677.
   PubMed Web of Science ®Google Scholar
• HOEG JM: Can genes prevent atherosclerosis. JAMA(1996) 276:989–992.
   Google Scholar
• KOPFLER WP, WILLARD M, BETY T: Adenovirus-mediated transfer of a gene encoding human apo A-I into normal mice increases circulating high density lipoprotein cholesterol. Circulation (1994) 90:1319–1327.
   PubMed Web of Science ®Google Scholar
• HAVEL RJ, YAMADA N, SHAMES DM: Role of apolipopro-tein E in lipoprotein metabolism. Am. Heart J. (1987) 113:470–474.
   Google Scholar
• WILLNOW TE, SHENG Z, ISHIBASHI S, HERZ J: Inhibitionof hepatic chylomicron remnant uptake by gene trans-fer of a receptor antagonist. Science (1994) 264:1471–1474.
   PubMedGoogle Scholar
• ZHANG SH, REDDICK RL, PIEDRAHITA JA, MAEDA N: Spontaneous hypercholesterolaemia and arterial le-sions in mice lacking apolipoprotein E. Science (1992) 258:468–471.
   PubMed Web of Science ®Google Scholar
• YAMADA N, SHIMANO H, MOKUNO H et al: Increasedclearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipi-demic rabbits. Proc. Natl. Acad. Sci. USA (1989) 86:665–669.
   Google Scholar
• KASHYAP VS, SANTAMARINA-FOJO S, BROWN DR et al.:Apolipoprotein E deficiency in mice: gene replace-ment and prevention of atherosclerosis using adeno-virus vectors. J. Clin. Invest. (1995) 96:1612–1620.
   PubMed Web of Science ®Google Scholar
• ECKEL RH: Lipoprotein lipase. A multifunctional en-zyme relevant to common metabolic disease. New Engl. J. Med. (1989) 320:1060–1068.
   Google Scholar
• DE BRUIN TW, MAILLY F, VAN BARLINGEN HHJJ et al.:Lipoprotein lipase gene mutations D9N and N2919 in four pedigrees with familial combined hypercholes-terolaemia. Eur. j Clin. Invest. (1996) 26:631–639.
   Google Scholar
• ASHBOURNE-EXCOFFIN KJD, LIU G, MIAO L et al.: Cor-rection of hypertriglyceridemia and impaired fat tol-erance in lipoprotein lipase-deficient mice by adenovirius-mediated expression of human lipopro-tein lipase. Arteriocler. Thromb. Vasc. Biol. (1997) 17:2532–2539.
   Google Scholar
• LEINWAND LA, KITSIS RN, BUTTRICK P et al.: Gene trans-fer into the adult mammalian heart in vivo. J. Cell Physiol. (1993) 17D:193.
   Google Scholar
• BARR E, BOLLING S, PARMACEK MS et al.: Gene transferinto cardiac and skeletal myocytes in vivo. J. Cell Physiol. (1993) 17D:192.
   Google Scholar
• SCHNEIDER MD, FRENCH BA: The advent of adenovirus: therapy for cardiovascular disease. Circulation (1993) 88:1937–1942.
   PubMed Web of Science ®Google Scholar
• AKHTAR SA, SKAER CA, KYPSON AP et al: Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc. Natl. Acad. ScL USA (1997) 94:12100–12105.
   Google Scholar
• OHNO T, GORDON D, SAN H et al.: Gene therapy for vas-cular smooth muscle proliferation after arterial in-jury. Science (1994) 265:781–784.
   PubMed Web of Science ®Google Scholar
• NABEL EG: Gene therapy for cardiovascular disease. Circulation (1995) 91:541–548.
   PubMed Web of Science ®Google Scholar
• GIBBONS GH, DZAU VJ: Molecular therapies for vascu-lar diseases. Science (1996) 272:689–693.
   PubMed Web of Science ®Google Scholar
• HIGASHIYAMA S, ABRAHAM JA, KLAGSBRUN M: Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interac-tions with cell surface heparan sulfate. J. Cell Biol. (1993) 122:933–940.
   PubMed Web of Science ®Google Scholar
• YOSHIZUMI M, KOUREMBANAS S, TEMIZER DH et al.: Tu-mor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J. Cell Biol. (1992) 267:9467–9469.
   Google Scholar
• BARRY WH: Mechanism of immune-mediated myocyte injury. Circulation (1994) 89:2421–2432.
   PubMedGoogle Scholar
• BRAUNER R, WU L, LAKS H: Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: methods and efficacy of adenovirus-mediated trans-duction. J. Thorac. Cardiovasc. Surg. (1997) 113:1059–1067.
   PubMed Web of Science ®Google Scholar
• HANCOCK WW, SAYEGH MH, ZHENG XG eta].: Costimu-latory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft re-jection. Proc. Natl. Acad. ScL USA (1996) 93:13967–13972.
   Google Scholar
• WOOD KJ: Gene therapy and allotransplantation. Curr. Opin. Immunol. (1997) 9:662–668.
   Google Scholar
• DELASANDRO J, AKIMOTO H, GORMAN C et al.: Gene therapy for donor hearts: ex vivo liposome-mediated transfection. j Thorac. Cardiovasc. Surg. (1996) 111:416–422.
   Google Scholar
• RISAU W: Mechanism of angiogenesis. Nature (1997)386:671–674.
   PubMed Web of Science ®Google Scholar
• WARE JA, SIMONS M: Angiogenesis in ischaemic heart disease. Nature Med. (1997) 3:158–164.
   PubMed Web of Science ®Google Scholar
• HANAHAN D: Signaling vascular morphogenesis and maintenance. Science (1997) 277:48–50.
   PubMed Web of Science ®Google Scholar
• TAKESHITA S, TSURUM Y, COUFFINAHT T et al.: Genetransfer of naked DNA encoding for three isoforms of vascular endothelial cell growth factor stimulates col-lateral development in vivo. Lab. Invest. (1996) 2:534–539.
   Google Scholar
• GIORDANO FJ, PING P, MAKIRNAN D et al. Intracoro- gene transfer of fibroblast growth factor-5 in-creases blood flow and contractile function in an region of the heart. Nature Med. (1996) 2:534–539.
   PubMed Web of Science ®Google Scholar
• SAFI J JR, GLOE TR, DIPAULA AF JR et al.: Adenovirus-mediated gene transfer of acidic fibroblast growth fac-tor reduces the risk region in a rabbit model of myo-cardial infarction. Circulation (1996) 94:1–590.
   Google Scholar
• TAKESHITA S, WEIR L, CHEN D et al.: Therapeutic angio-genesis following arterial gene transfer of vascular en-dothelial cell growth factor in a rabbit model of hind limb ischaemia. Biochem. Biophys. Res. Commun. (1996) 227:628–635.
   PubMed Web of Science ®Google Scholar
• HIROTSUGU T, SILVER M, ISNER JM: Arterial gene trans-fer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc. Res. (1997) 227:628–635.
   Google Scholar